Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Yamauchi T, Kitai R, Kodera T, Arishima H, Matsuda K, Isozaki M, Ishida S, Matta Y, Kanamoto M, Kimura H, Kikuta K. Comparison of amide proton transfer imaging with perfusion imaging of using arterial spin-labeling for evidence of tumor invasion in glioblastoma. Interdisciplinary Neurosurgery 2022;28:101461. [DOI: 10.1016/j.inat.2021.101461] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open

For:	Yamauchi T, Kitai R, Kodera T, Arishima H, Matsuda K, Isozaki M, Ishida S, Matta Y, Kanamoto M, Kimura H, Kikuta K. Comparison of amide proton transfer imaging with perfusion imaging of using arterial spin-labeling for evidence of tumor invasion in glioblastoma. Interdisciplinary Neurosurgery 2022;28:101461. [DOI: 10.1016/j.inat.2021.101461] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open

Number

Cited by Other Article(s)

Fatania K, Frood R, Tyyger M, McDermott G, Fernandez S, Shaw GC, Boissinot M, Salvatore D, Ottobrini L, Teh I, Wright J, Bailey MA, Koch-Paszkowski J, Schneider JE, Buckley DL, Murray L, Scarsbrook A, Short SC, Currie S. Exploratory Analysis of Serial ¹⁸F-fluciclovine PET-CT and Multiparametric MRI during Chemoradiation for Glioblastoma. Cancers (Basel) 2022;14:3485. [PMID: 35884545 PMCID: PMC9315674 DOI: 10.3390/cancers14143485] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2022] [Revised: 07/11/2022] [Accepted: 07/15/2022] [Indexed: 12/03/2022] Open

Abstract

Anti-1-amino-3-18fluorine-fluorocyclobutane-1-carboxylic acid (18F-fluciclovine) positron emission tomography (PET) shows preferential glioma uptake but there is little data on how uptake correlates with post-contrast T1-weighted (Gd-T1) and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) activity during adjuvant treatment. This pilot study aimed to compare 18F-fluciclovine PET, DCE-MRI and Gd-T1 in patients undergoing chemoradiotherapy for glioblastoma (GBM), and in a parallel pre-clinical GBM model, to investigate correlation between 18F-fluciclovine uptake, MRI findings, and tumour biology. 18F-fluciclovine-PET-computed tomography (PET-CT) and MRI including DCE-MRI were acquired before, during and after adjuvant chemoradiotherapy (60 Gy in 30 fractions with temozolomide) in GBM patients. MRI volumes were manually contoured; PET volumes were defined using semi-automatic thresholding. The similarity of the PET and DCE-MRI volumes outside the Gd-T1 volume boundary was measured using the Dice similarity coefficient (DSC). CT-2A tumour-bearing mice underwent MRI and 18F-fluciclovine PET-CT. Post-mortem mice brains underwent immunohistochemistry staining for ASCT2 (amino acid transporter), nestin (stemness) and Ki-67 (proliferation) to assess for biologically active tumour. 6 patients were recruited (GBM 1-6) and grouped according to overall survival (OS)-short survival (GBM-SS, median OS 249 days) and long survival (GBM-LS, median 903 days). For GBM-SS, PET tumour volumes were greater than DCE-MRI, in turn greater than Gd-T1. For GBM-LS, Gd-T1 and DCE-MRI were greater than PET. Tumour-specific 18F-fluciclovine uptake on pre-clinical PET-CT corresponded to immunostaining for Ki-67, nestin and ASCT2. Results suggest volumes of 18F-fluciclovine-PET activity beyond that depicted by DCE-MRI and Gd-T1 are associated with poorer prognosis in patients undergoing chemoradiotherapy for GBM. The pre-clinical model confirmed 18F-fluciclovine uptake reflected biologically active tumour.

Collapse

Affiliation(s)

Kavi Fatania Department of Radiology, Leeds Teaching Hospitals Trust, Leeds General Infirmary, Leeds LS1 3EX, UK; (R.F.); (A.S.); (S.C.) Leeds Institute of Medical Research, University of Leeds, Leeds LS2 9TJ, UK; (G.C.S.); (M.B.); (L.M.); (S.C.S.)
Russell Frood Department of Radiology, Leeds Teaching Hospitals Trust, Leeds General Infirmary, Leeds LS1 3EX, UK; (R.F.); (A.S.); (S.C.)
Marcus Tyyger Department of Medical Physics, Leeds Teaching Hospitals Trust, St James’s University Hospital, Leeds LS9 7TF, UK; (M.T.); (G.M.)
Garry McDermott Department of Medical Physics, Leeds Teaching Hospitals Trust, St James’s University Hospital, Leeds LS9 7TF, UK; (M.T.); (G.M.)
Sharon Fernandez Department of Clinical Oncology, Leeds Teaching Hospitals Trust, St James’s University Hospital, Leeds LS9 7TF, UK;
Gary C. Shaw Leeds Institute of Medical Research, University of Leeds, Leeds LS2 9TJ, UK; (G.C.S.); (M.B.); (L.M.); (S.C.S.)
Marjorie Boissinot Leeds Institute of Medical Research, University of Leeds, Leeds LS2 9TJ, UK; (G.C.S.); (M.B.); (L.M.); (S.C.S.)
Daniela Salvatore Department of Pathophysiology and Transplantation, University of Milan, 20122 Segrate, Italy; (D.S.); (L.O.)
Luisa Ottobrini Department of Pathophysiology and Transplantation, University of Milan, 20122 Segrate, Italy; (D.S.); (L.O.) Institute of Molecular Bioimaging and Physiology, National Research Council (IBFM-CNR), 20054 Segrate, Italy
Irvin Teh Biomedical Imaging Science Department, and Discovery & Translational Science Department, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds LS2 9TJ, UK; (I.T.); (J.W.); (M.A.B.); (J.K.-P.); (J.E.S.); (D.L.B.)
John Wright Biomedical Imaging Science Department, and Discovery & Translational Science Department, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds LS2 9TJ, UK; (I.T.); (J.W.); (M.A.B.); (J.K.-P.); (J.E.S.); (D.L.B.)
Marc A. Bailey Biomedical Imaging Science Department, and Discovery & Translational Science Department, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds LS2 9TJ, UK; (I.T.); (J.W.); (M.A.B.); (J.K.-P.); (J.E.S.); (D.L.B.) Leeds Vascular Institute, Leeds Teaching Hospitals Trust, Leeds General Infirmary, Leeds LS1 3EX, UK
Joanna Koch-Paszkowski Biomedical Imaging Science Department, and Discovery & Translational Science Department, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds LS2 9TJ, UK; (I.T.); (J.W.); (M.A.B.); (J.K.-P.); (J.E.S.); (D.L.B.)
Jurgen E. Schneider Biomedical Imaging Science Department, and Discovery & Translational Science Department, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds LS2 9TJ, UK; (I.T.); (J.W.); (M.A.B.); (J.K.-P.); (J.E.S.); (D.L.B.)
David L. Buckley Biomedical Imaging Science Department, and Discovery & Translational Science Department, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds LS2 9TJ, UK; (I.T.); (J.W.); (M.A.B.); (J.K.-P.); (J.E.S.); (D.L.B.)
Louise Murray Leeds Institute of Medical Research, University of Leeds, Leeds LS2 9TJ, UK; (G.C.S.); (M.B.); (L.M.); (S.C.S.) Department of Clinical Oncology, Leeds Teaching Hospitals Trust, St James’s University Hospital, Leeds LS9 7TF, UK;
Andrew Scarsbrook Department of Radiology, Leeds Teaching Hospitals Trust, Leeds General Infirmary, Leeds LS1 3EX, UK; (R.F.); (A.S.); (S.C.) Leeds Institute of Medical Research, University of Leeds, Leeds LS2 9TJ, UK; (G.C.S.); (M.B.); (L.M.); (S.C.S.)
Susan C. Short Leeds Institute of Medical Research, University of Leeds, Leeds LS2 9TJ, UK; (G.C.S.); (M.B.); (L.M.); (S.C.S.) Department of Clinical Oncology, Leeds Teaching Hospitals Trust, St James’s University Hospital, Leeds LS9 7TF, UK;
Stuart Currie Department of Radiology, Leeds Teaching Hospitals Trust, Leeds General Infirmary, Leeds LS1 3EX, UK; (R.F.); (A.S.); (S.C.) Leeds Institute of Medical Research, University of Leeds, Leeds LS2 9TJ, UK; (G.C.S.); (M.B.); (L.M.); (S.C.S.)

Collapse